Orthocell wins first international approval for nerve repair product
West Australia-based regenerative medicine play Orthocell (ASX: OCC) has received regulatory approval from the Health Sciences Authority in Singapore.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
C2F | Ann: C2F FY24 Statutory Accounts | 22/08/24 | 0 | 89 | |||
|
|||||||
C2F | Ann: C2F Q4 FY24 Quarterly Report | 30/07/24 | 0 | 97 | |||
|
|||||||
C2F | Ann: Interest Payment - C2FHA | 25/07/24 | 0 | 192 | |||
|
|||||||
C2F | Ann: C2F Q3 FY24 Quarterly Report | 30/04/24 | 0 | 160 | |||
|
|||||||
C2F | Ann: Interest Payment - C2FHA | 24/04/24 | 0 | 245 | |||
|
|||||||
C2F | Ann: C2F HY24 Statutory Accounts | 20/02/24 | 0 | 141 | |||
|
|||||||
C2F | Ann: Interest Payment - C2FHA | 23/01/24 | 0 | 216 | |||
|
|||||||
C2F | Ann: C2F Q2 FY24 Quarterly Report | 23/01/24 | 0 | 130 | |||
|
See All Discussions
Timeline
|
|||||
|
|||||
|
|||||
|
|||||
|
|||||
|
|||||
View More |